Effect of intravenous iron supply in patients with heart failure with reduced ejection fraction – a literature review
DOI:
https://doi.org/10.12775/QS.2024.35.56338Keywords
heart failure, iron deficiency, intravenous ferric carboxymaltose, intravenous ferric derisomaltoseAbstract
Introduction and Purpose
Iron deficiency in patients with heart failure is a common problem of which they are often unaware. It is associated with a worse prognosis compared to patients suffering with heart failure without iron deficiency. An important point in the diagnosis in patients with heart failure would be the determination of iron in the blood, in order to catch patients eligible for intravenous iron administration. The aim of the study was to investigate whether intravenous iron administration could affect quality of life in these patients and further reduce hospital admissions for heart failure exacerbations and deaths caused by cardiovascular events.
Material and Methods
A comprehensive literature review was conducted using the PubMed and Google Scholar database. We used the key words: ‘heart failure’ in combination with medical terms referring to iron status or its therapeutic use , “iron deficiency”, “intravenous iron”, “intravenous ferric carboxymaltose”, “intravenous ferric derisomaltose” in various combinations.
Results and conclusions
Intravenous iron administration in patient with heart failure with reduced ejection fraction and iron deficiency reduces symptoms, improves quality of life, exercise tolerance and reduces hospital admissions for heart failure. It is very important to actively look for iron deficiency in patients with heart failure, and then patients who meet the criteria should be provided with an intravenous iron administration.
References
Cairo G, Bernuzzi F, Recalcati S. A precious metal: Iron, an essential nutrient for all cells. Genes Nutr. 2006;1(1):25-39. doi:10.1007/BF02829934
Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci. 2009;66(20):3241-3261. doi:10.1007/s00018-009-0051-1
Núñez J, Comín-Colet J, Miñana G, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure [published correction appears in Eur J Heart Fail. 2022 Mar;24(3):591. doi: 10.1002/ejhf.2396]. Eur J Heart Fail. 2016;18(7):798-802. doi:10.1002/ejhf.513
Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure [published correction appears in Eur Heart J. 2011 May;32(9):1054]. Eur Heart J. 2010;31(15):1872-1880. doi:10.1093/eurheartj/ehq158
Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013;34(11):816-829. doi:10.1093/eurheartj/ehs224
Tymińska A, Sypień P, Ozierański K, Opolski G. Anemia and iron deficiency in patients with heart failure — diagnostic and therapeutic management. Folia Cardiologica. 2017 September, 12(4), 422 – 430. doi: 10.5603/FC.2017.0077
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2022 May 3;145(18):e1033. doi: 10.1161/CIR.0000000000001073] [published correction appears in Circulation. 2022 Sep 27;146(13):e185. doi: 10.1161/CIR.0000000000001097] [published correction appears in Circulation. 2023 Apr 4;147(14):e674. doi: 10.1161/CIR.0000000000001142]. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. doi:10.1002/ejhf.1858
Rocha BML, Cunha GJL, Menezes Falcão LF. The Burden of Iron Deficiency in Heart Failure: Therapeutic Approach. J Am Coll Cardiol. 2018;71(7):782-793. doi:10.1016/j.jacc.2017.12.027
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670]. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
Skotnicka J, Błaszczak K, Witkowska M, Turek M, Witkowski M, Ślósarz T, Krupa P, Kaczorowski R, Forenc T, Wojciechowska K. Changes in the Treatment and Prevention of Heart Failure Based on the 2023 Focused Update of the 2021 European Society of Cardiology Guidelines. Quality in Sport. 24, (Oct. 2024), 54787. DOI:https://doi.org/10.12775/QS.2024.24.54787.
Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5-37.
Masini G, Graham FJ, Pellicori P, et al. Criteria for Iron Deficiency in Patients With Heart Failure. J Am Coll Cardiol. 2022;79(4):341-351. doi:10.1016/j.jacc.2021.11.039
Cohen-Solal A, Leclercq C, Deray G, et al. Iron deficiency: an emerging therapeutic target in heart failure. Heart. 2014;100(18):1414-1420. doi:10.1136/heartjnl-2014-305669
Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-582.e3. doi:10.1016/j.ahj.2013.01.017
Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol. 2014;174(2):268-275. doi:10.1016/j.ijcard.2014.03.169
Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125-133. doi:10.1002/ejhf.823
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015;36(11):657-668. doi:10.1093/eurheartj/ehu385
Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial [published correction appears in Lancet. 2021 Nov 27;398(10315):1964. doi: 10.1016/S0140-6736(21)02492-2]. Lancet. 2020;396(10266):1895-1904. doi:10.1016/S0140-6736(20)32339-4
Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199-2209. doi:10.1016/S0140-6736(22)02083-9
Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-2448. doi:10.1056/NEJMoa0908355
Lewis GD, Malhotra R, Hernandez AF, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial [published correction appears in JAMA. 2017 Jun 20;317(23):2453. doi: 10.1001/jama.2017.7019]. JAMA. 2017;317(19):1958-1966. doi:10.1001/jama.2017.5427
Jankowska EA, Kasztura M, Sokolski M, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35(36):2468-2476. doi:10.1093/eurheartj/ehu235
Sawicki KT, Ardehali H. Intravenous Iron Therapy in Heart Failure With Reduced Ejection Fraction: Tackling the Deficiency. Circulation. 2021;144(4):253-255. doi:10.1161/CIRCULATIONAHA.121.054271
Graham FJ, Pellicori P, Ford I, Petrie MC, Kalra PR, Cleland JGF. Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clin Res Cardiol. 2021;110(8):1299-1307. doi:10.1007/s00392-021-01837-8
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Katarzyna Dąbek, Michał Ochwat, Maria Sudoł, Martyna Piekarska, Gabriela Mierzwa, Aleksandra Kajtel, Anna Skowronek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 15
Number of citations: 0